1. Identification of Novel Molecular Therapeutic Targets and Their Potential Prognostic Biomarkers Based on Cytolytic Activity in Skin Cutaneous Melanoma
   Haoxue Zhang et al, 2022, Frontiers in Oncology CrossRef
2. YY1 Is a Key Player in Melanoma Immunotherapy/Targeted Treatment Resistance
   Dominika Kwiatkowska et al, 2022, Frontiers in Oncology CrossRef
3. Novel Phthalic-Based Anticancer Tyrosine Kinase Inhibitors: Design, Synthesis and Biological Activity
   Elena Kalinichenko et al, 2023, Current Issues in Molecular Biology CrossRef
4. In vitro and in silico study on the effect of carvedilol and sorafenib alone and in combination on the growth and inflammatory response of melanoma cells
   Joanna Wawszczyk et al, 2023, Saudi Pharmaceutical Journal CrossRef
5. Angiogenesis Still Plays a Crucial Role in Human Melanoma Progression
   Gerardo Cazzato et al, 2024, Cancers CrossRef
6. Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma
   Rasha M. Allam et al, 2024, Bioorganic Chemistry CrossRef
7. Recent advances in tyrosine kinase inhibitors VEGFR 1-3 for the treatment of advanced metastatic melanoma
   Paweł Sobczuk et al, 2024, Expert Opinion on Pharmacotherapy CrossRef
8. Neuropilin-2 Inhibits Drug Resistance and Progression of Melanoma Involving the MiR-331-3p Regulated Cascade
   Dandan Liu et al, 2023, Current Molecular Pharmacology CrossRef